Cycloserine
Brand names: Specialist UKHSA supply
Cycloserine is a second-line antituberculous agent used within multidrug regimens for drug-resistant tuberculosis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a structural analogue of D-alanine it inhibits enzymes involved in bacterial cell-wall synthesis (alanine racemase and D-alanine ligase), impairing peptidoglycan formation.
Prescribing in practice
- Central nervous system toxicity is the key concern, ranging from headache and confusion to depression, psychosis, seizures and suicidal ideation, and it should be avoided or used with great caution in epilepsy, depression or severe psychiatric illness.
- Pyridoxine is usually co-prescribed to reduce neurotoxicity, and alcohol increases the seizure risk.
- It requires dose adjustment in renal impairment as it is renally cleared.
Monitoring
Monitor mental state and neurological status closely, with plasma-concentration monitoring used in specialist practice to limit toxicity.
Counselling the patient
- Report low mood, unusual thoughts, confusion or any fit promptly.
- Take the pyridoxine prescribed alongside it and avoid alcohol.
- Do not stop abruptly without specialist advice.
Evidence & guidelines
Use is grounded in WHO and national guidance for drug-resistant tuberculosis regimens.
Reference: WHO MDR-TB guideline; BTS/SIGN; UKHSA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023